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Summary 
 
Thrombosis is central to the pathogenesis of many life-threatening diseases, 
including stroke and myocardial infarction. Current treatments for thrombosis, 
particularly anti-platelet agents that target GPIIb/IIIa, can cause serious 
bleeding complications. Unlike GPIIb/IIIa, GPIb initiates thrombus formation at 
the high shear stress that is prominent in atherosclerotic vessels. Therefore, 
this target could prevent pathological thrombosis while leaving normal 
haemostasis at low shear rates relatively unaffected. Anfibatide is a novel 
GPIb antagonist isolated from snake venom in China. Anfibatide will enter 
phase Ib-IIa trials in early 2015 and therefore, it is necessary to develop an 
assay to measure its efficacy in patients. We have developed a flow cytometry 
based receptor occupancy assay. In this assay, total GPIb receptor numbers 
are measured using an anti-GPIb monoclonal antibody, and the percentage of 
GPIb receptor occupancy by anfibatide is measured. Receptor occupancy by 
anfibatide correlated with dose-dependent inhibition of ristocetin-induced 
aggregation in whole blood by anfibatide. Functional studies were carried out 
using anfibatide. Anfibatide did not inhibit binding of two anti-GPIIb/IIIa 
antibodies. Anfibatide partially inhibited the anti-GPIb antibodies VM16d, and 
SZ 2, indicating that it binds to GPIbα between the thrombin-binding site and 
the sulfated tyrosine motif. Anfibatide did not cause platelet activation or loss 
of single platelets in vitro. Anfibatide had no effect on aggregation induced by 
low dose or high dose thrombin, ADP or arachidonic acid. Anfibatide inhibited 
Streptococcus sanguinis 133-79 induced aggregation by 50% in half of 
healthy donors, but had no effect on Staphylococcus aureus Newman 
aggregation. The receptor occupancy assay is optimised and available for use 
in Phase Ib-IIa clinical trials, and in future clinical use of anfibatide. 
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Chapter 1: Introduction 
 
Platelets are anucleate fragments from megakaryocytes. They are the 
smallest and most abundant cellular component of blood, ranging from 3 x 
108/ml to 4 x 108/ml. The GPIb-IX-V complex is present on the platelet 
membrane and interacts with von Willebrand factor to initiate thrombus 
formation at high shear stress. This interaction is central in pathological 
thrombus formation, which can lead to stroke and myocardial infarction. 
Thrombosis is treated with anti-platelet agents, usually targetting the 
GPIIb/IIIa receptor. This receptor causes thrombus formation at low shear 
stress, and its inhibition leads to bleeding complications. Since GPIb inhibition 
would not affect haemostasis at low shear stress in the periphery, it is an 
enticing target for anti-thrombotic treatment (1-6).  
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Glycoprotein Ib-IX-V Complex  
 
The glycoprotein (GP) Ib-IX-V complex is a receptor present on the platelet 
membrane with a central role in primary haemostasis under high shear 
conditions. GPIb binds to von Willebrand factor (vWF), which is exposed on 
the subendothelium following vascular damage, leading to thrombus formation 
(1-6). GPIb bound to the endothelium may mediate endothelial cell migration 
during wound repair (7). GPIb-IX-V has also been implicated in regulating 
platelet size (2). 
 
The GPIb-IX-V complex is part of the leucine rich repeat (LRR) family (3). The 
adhesion receptor contains four membrane spanning polypeptides (GPIbα, 
GPIbβ, GPIX and GPV) in the ratio 2:2:2:1 on the platelet plasma membrane 
(5). GPIbα (610 residues) is disulfide linked to GPIbβ (181 residues), and is 
noncovalently complexed with GPIX (160 residues) and GPV (544 residues) 
(2). A stable complex between GPIbα, GPIbβ, and GPIX is required for 
normal transport of each gene product though the membrane systems of 
maturing megakaryocytes, as well as for expression of the complex on the 
platelet surface (8). GPV has a high affinity binding site for thrombin (9). The 
LRRs on GPIX, GPIbβ, and GPV may be vital in controlling subunit structure 
(8). GPIb-IX-V is formed in the endoplasmic reticulum and transported to the 
Golgi apparatus for subsequent modification, including O-glycosylation of 
GPIbα (8,10). GPIb-V-IX is extensively palmitoylated (11). A GPIb-V-IX 
subset is constitutively associated with lipid rafts in unstimulated platelets, and 
the number of receptors present can triple following stimulation with vWF (11, 
12). Lipid raft disruption impairs some GPIb-IX-V dependent reactions, 
including vWF induced aggregation, tyrosine phosphorylation and adhesion to 
vWF (11). 
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GPIb (CD42b) 
The largest subunit in the GPIb-IX-V complex is GPIbα, which has an 
apparent molecular mass of 135 kDa (2, 6). It is a major sialoglycoprotein with 
multiple N- and O- linked oligosaccharides (10). The N-terminal domain (1- 
282 residues) of GPIbα contains binding sites for vWF (amino acids 26-200), 
Mac-1 (on neutrophils), P-selectin (on activated platelets and endothelial 
cells), α-thrombin (a potent platelet agonist in vivo), clotting factors XI/XIIa, 
and high-molecular-weight kininogen (2, 6, 13). Glycocalicin, a soluble 
fragment of GPIb, is produced by proteolytic cleavage, for example by 
endogenous platelet calpain, of the external part of GPIbα. Glycocalicin 
circulates freely in normal plasma (10, 14). GPIb interaction with its ligands 
generally involves large protein-protein interactions (15). GPIb usually binds 
thrombin when the agonist is present at low doses, due to the high affinity of 
the binding site (4, 13, 16). Heparin blocks thrombin induced platelet 
activation through GPIb (4). The N- terminal domain of GPIbα is enclosed by 
two conserved disulphide loop structures, and contains eight LRRs (12). 
Asparagine residues in these LRRs are required for correct conformation and 
function of the ligand binding regions (17). LRRs 2, 3, and 4 are critical for 
vWF binding and platelet adhesion. Residues 283-302 are mostly negatively 
charged, and include aspartic and glutamic acids, and three sulfated tyrosines 
(Tyr276, Tyr278, Tyr279). Mutation of the three sulfated tyrosine residues strongly 
reduces vWF levels, and thrombin binding (12). It is suggested that this 
sulfated region is necessary for GPIbα to bind vWF under shear flow (9). A 
long and highly glycosylated mucin-like macroglycopeptide domain with a 
molecular mass of 118 kDa (residues 303-485) connects these to a single 
transmembrane region (residues 486-514) (12, 18). The macroglycopeptide 
may position the ligand-binding region above other molecules present on the 
platelet surface (9). The cytoplasmic tail of GPIbα consists of 96 amino acids 
(residues 515-610) and is necessary for normal processing and function of 
GPIb-V-IX (12). Filamin-1 binds to residues 557-579, and adaptor protein 
14.3.3ζ binds to residues 605-610 (19). 
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Some reports estimate 25,000 GPIbα receptors per platelet (5, 6, 13), but this 
remains controversial. Yamamoto et al reported approximately 28,000 GPIb 
molecules per platelet using a monoclonal antibody that binds to a part of 
glycocalicin containing overlapped binding sites for vWF and thrombin (20). 
Other monoclonal antibody studies indicate that there are 20,000 to 25,000 
receptors per platelet, compared to 40,000 to 50,000 receptors indicated in 
studies using monovalent snake venom C-type lectins. Recent flow cytometry 
studies generally support higher receptor numbers, suggesting that the 
divalent nature of the monoclonal antibodies was not considered in the earlier 
studies (15).  
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Von Willebrand Factor 
 
Von Willebrand factor (vWF) is a multimeric glycoprotein bound to collagen in 
the subendothelial matrix or plasma (21). It circulates in the plasma tightly 
bound to the glycoprotein factor VIII (FVIII). FVIII accelerates activation of 
factor X by activated factor IX in the coagulation cascade. VWF has an 
important role in production, conformation, and stabilisation of FVIII (12). 
Mature vWF is 250 kDa, with 2,050 amino acids, and is characterised by A, B, 
C, and D structural domains. It is rapidly secreted as a range of multimers 
(over 2,000 kDa) from endothelial Weibel-Palade bodies and platelet α-
granules following endothelial or platelet activation by pro-thrombotic or 
inflammatory signals (2, 12, 22, 23). Patients with coronary heart disease tend 
to have high vWF concentration, and have more ultralarge multimers than 
healthy people (24). VWF is exposed on the endothelium following vascular 
damage, which can occur acutely or chronically by several pathophysiological 
mechanisms, allowing it to interact with GPIb (3, 25). GPIb-IX-V binds vWF in 
a bidentate interaction, initiating platelet aggregation and leading to thrombus 
formation at high shear rates in flowing blood (3, 4). VWF binding to GPIb-V-
IX involves vWF A1 domain and the 45 kDa extra-cellular N-terminal domain 
of GPIbα (Figure 1.1) (2, 12). The co-crystal structures of GPIb (residues 1–
267) and the vWF A1 domain (residues 478–705) show involvement of N-
terminal (-hairpin) and C-terminal (“-switch”) flanking sequences. GPIb 
residues in the N-terminal flank, the LRRs, and the C-terminal flank directly 
interact with vWF A1. The LRR sequence 59–128 is critical for vWF binding 
under static or shear conditions using human or canine chimaeras of GPIb 
expressed on CHO cells (2). The A1 domain of activated soluble vWF 
requires a conformational change to increase its affinity for GPIb-V-IX. Under 
physiological conditions, this change occurs when vWF is bound in the 
extracellular matrix, or under hydrodynamic shear stress (12). 
 16 
GPIb-vWF Interaction 
 
Platelets become activated after adhering to vWF and undergo cytoskeletal 
rearrangement associated with shape change, spreading and secretion of 
platelet agonists, for example adenosine di-phosphate (ADP), which recruits 
additional platelets to the developing thrombus (2, 26). VWF can 
simultaneously bind different GPIb-V-IX receptors on adjacent platelets, 
possibly contributing directly to receptor clustering and activation, and 
aggregate formation (11,12). GPIbα is involved in the transient binding of 
platelets to activated vWF at sites of vascular injury (4). GPIbα binding to vWF 
initiates platelet tethering to the subendothelial matrix, as well as transient 
platelet translocation across the matrix surface (9). This binding reduces 
platelet velocity in flowing blood, causing “rolling” of platelets. This allows vWF 
to efficiently capture platelets, initiating platelet deposition and thrombus 
formation (10, 12). Using a parallel plate flow chamber model, ex vivo 
platelets adhere transiently and roll on immobilized vWF under flow 
conditions. Rolling platelets become arrested on the vWF matrix when shear 
stress increased dramatically. This shear stress model is representative of 
arterial stenosis in vivo (27). Low GPIbα receptor density has been associated 
with increased cell velocity during this rolling phenomenon, compared to cells 
with high receptor density. GPV may also be necessary for optimum binding 
of vWF and GPIbα (9). Intracellular signal transduction leads to mobilisation 
of a src kinase and phospholipase Cγ2 activation. Release of internal Ca2+ 
stores follows, which causes rearrangement of the cytoskeleton, and platelet 
shape change with filipodia extension (28, 29). The platelet surface integrin 
GPIIb/IIIa (αIIbβ3) is also activated, binding fibrinogen and mediating platelet 
aggregation (2, 26, 29). GPIb-V-IX is also an indirect collagen receptor 
through the A3 domain of vWF, and possibly the A1 domain (15).  
 
The surface expression of the GPIb-V-IX complex is downregulated following 
platelet activation. This could possibly be a mechanism to prevent excessive 
thrombus growth (15). Thrombus growth and thrombolysis are dynamic 
processes and may occur simultaneously. Inhibition of the GPIb-vWF 
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interaction may stop platelet recruitment and shift thrombus growth toward 
dissolution under shear flow. The GPIb-vWF interaction leads to ‘outside-in’ 
signaling via the GPIb-IX-V complex, stimulating GPIIb/IIIa activation in the 
thrombus (4, 26). This is necessary for platelet aggregation mediated by 
fibrinogen, and other integrin ligands (26). 
 
 
Figure 1.1. The structure of the vWF A1 domain (shown in red) and GPIbα (shown in 
blue), (PDB: 1M10)
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GPIIb/IIIa 
 
Fibrinogen, the main ligand for GPIIb/IIIa, is a plasma glycoprotein that plays 
a critical role in platelet aggregation as well as in the formation of a fibrin clot 
at the site of vascular injury. When the coagulation cascade is triggered, the 
resulting thrombin activates platelets and converts fibrinogen into fibrin 
monomers. GPIIb/IIIa changes conformation following platelet activation 
allowing binding of fibrinogen. This process is the final common pathway for 
platelet aggregation stimulated by ADP, thrombin, or collagen. GPIIb/IIIa 
contains two RGD sequences in the α-chain (residues 95-97), and a C- 
terminal dodecapeptide on the γ-chain (residues 400–411). RGD peptides 
bind to residues 109–171 of GPIIIa, and γ-chain dodecapeptides bind to 
residues 294–314 of GPIIb. The RGD sequences and the AGDV sequence 
from the dodecapeptide share the same binding site in GPIIb/IIIa, spanning 
both chains IIb and IIIa (31). There are between 60,000 and 80,000 GPIIb/IIIa 
receptors per platelet (30). GPIIb/IIIa levels are lower in patients with 
Glanzmann’s thrombasthenia compared to healthy people, resulting in 
abnormal clot retraction, prolonged bleeding time, and the absence of platelet 
aggregation (32). These interactions are central in vascular inflammation and 
thrombosis. 
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Shear Conditions in Flowing Blood 
 
Under high shear stress, as found in the arteries, large particles, including 
erythrocytes, accumulate in the centre of blood flow, forcing the smaller 
platelets to the periphery, allowing them to interact with the endothelium (33). 
The interaction of the GPIb-IX-V complex with vWF has a vital role in the 
initiation of platelet adhesion, particularly at high shear rates (> 1,200 s-1), and 
is necessary for complete vessel occlusion above a limiting shear rate 
(approximately 10,000 s-1). At sites of vascular stenosis, blood flow velocity 
increases due to lumen restriction, thus increasing the shear stress on 
platelets. Complete thrombotic occlusion of vessels initiated by the GPIb-vWF 
interaction, and completed by GPIIb/IIIa mediated thrombus formation and 
adhesion, causes blood flow obstruction and tissue damage (26). The GPIb- 
V-IX interaction with vWF can efficiently take place under high shear flow in 
arterioles and small arteries (10 - 50 Angstrom in diameter), where the shear 
rate varies from 500 s-1 to 5,000 s-1 (9, 12). Under this high shear stress, 
GPIbα has limited time to bind to vWF, and requires a strong bond to support 
and maintain adhesion (9). On the other hand, platelet surface integrin 
GPIIb/IIIa and its ligands, including fibrinogen, mediate platelet aggregation 
and contribute to platelet adhesion at low shear stress in larger arteries and 
veins (9, 12, 26).  
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In Vitro Activation of GPIb 
 
Soluble vWF can be activated artificially in vitro to bind GPIb-V-IX in the 
absence of shear stress or vWF immobilisation by ristocetin and botrocetin. 
Ristocetin is an antibiotic glycopeptide isolated from the soil bacterium 
Nocardia lurida, and botrocetin is derived from a snake venom toxin (12, 34). 
Ristocetin binds to proline rich sequences contained in the anionic sequences 
of the A1 domain of vWF (Cys1237-Pro1251 and Glu1463-Asp1472) (12, 34). 
Botrocetin binds to one or more sequences within the disulphide loop 
(residues 539-643) of the A1 domain (12). The sulfated tyrosine residues are 
important for the botrocetin-induced reaction with GPIb and vWF (35). Both 
ristocetin and botrocetin change the conformation of the vWF A1 domain to 
allow binding of GPIb, in turn causing platelet aggregation in vitro (26). The 
action of ristocetin more closely mimics the GPIb-vWF interaction induced by 
shear stress in vivo (9, 34). Ristocetin- and botrocetin- induced binding of 
GPIb to vWF leads to signal transduction and GPIIb/IIIa activation (4). 
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Monoclonal Antibodies Directed Against GPIbα  
 
Expression of GPIbα on the platelet surface can be detected by flow 
cytometry analysis after incubation with labelled monoclonal antibodies. 
Several monoclonal antibodies directed against GPIbα are commonly used. 
 
AN51 is directed against amino acids 1-35 in the N-terminal of GPIbα. It 
blocks vWF binding to GPIbα (10). Binding studies using AN51 in platelet rich 
plasma (PRP) indicate 22,000 ± 2,700 binding sites (6), though this number 
tends to vary widely depending on the donor (9). AN51 is sensitive to 
reduction, suggesting that it is dependent on protein conformation (35). It has 
no effect on vWF binding induced by botrocetin or ristocetin (35). AN51 also 
reacts with monocytes (32).  
 
WM23 is an anti-GPIb murine monoclonal antibody, which binds to the 
macroglycopeptide region of GPIbα, without affecting binding to vWF (9, 11, 
36). It detects 21,000 ± 3,400 binding sites on platelets (6). 
 
SZ 2 binds to GPIbα (residues 276-282) in the highly negatively charged 
domain on GPIbα, which contains three sulfated tyrosine residues (8). This 
region is involved in thrombin binding. SZ 2 prevents thrombin generation by 
the prothrombinase complex, but does not significantly affect the numbers of, 
or mean velocity of, rolling mammalian cells across glass slides coated with 
vWF (4, 9, 35). SZ 2 blocks botrocetin-induced binding of vWF to GPIb, and 
weakly inhibits the ristocetin-induced reaction (9, 35). It is not sensitive to 
protein reduction (35).  
 
VM16d is directed towards the thrombin-binding site on GPIbα. It inhibits 
thrombin binding, but not vWF binding. It also blocks the procoagulant 
response of platelets to low doses, but not to high doses, of thrombin. VM16d 
does not prevent ristocetin-induced binding of vWf to GPIb when measured 
using flow cytometry (4).  
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ALMA 19 is a mouse monoclonal antibody that binds to GPIbα on human 
platelets and megakaryocytes. The exact binding site has not yet been 
established (19). 
 
Figure 1.2. Binding of anti-GPIbα antibodies. AN51 binds to the N-terminal (residues 1-
35), where vWF binds. VM16d binds to the thrombin-binding site. SZ 2 binds to residues 276-
282 in the sulfated tyrosine motif. WM23 binds to the macrogylycopeptide region. ALMA 19 
binds to GPIbα, though the exact binding site is unknown.
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Disorders of GPIb 
 
Bernard-Soulier syndrome (BSS) is an autosomal recessive bleeding disorder 
that occurs when a patient has deficient, absent, or dysfunctional GPIb-IX-V, 
or impaired maturation or processing of the complex (4, 8, 18, 37). 
Thrombocytopenia (a decrease in circulating platelet levels) and impaired 
platelet adhesion to vWF is observed in BSS patients, which may lead to 
severe and possibly fatal bleeding, and may require blood transfusion (8,18). 
BSS platelets are typically large, indicating a role for GPIb-IX-V in the 
regulation of platelet size (2). BSS platelets are round, and have abundant 
vacuoles (8). BSS patients show defective procoagulant activity, with high 
basal levels, and decreased levels when stimulated by agonists compared to 
healthy people. This may be due to reduced stability of the membrane (4). 
BSS patients have low sensitivity to thrombin, but platelets can still be 
activated at high doses of thrombin (4, 18, 20).  
 
BSS can be caused by sense or missense mutations in the GPIbα, GPIbβ or 
GPIX genes. The majority of reported cases involve a defect in the GPIbα 
gene, leading to a structurally modified or truncated protein with inhibited or 
absent expression of GPIbα. This is followed by reduced expression of GPIX 
and GPV on the platelet surface. One such mutation is the Cys209 to Ser 
missense mutation (8). The Bolzano variant of BSS is hereditary, caused by a 
point mutation of A156 to V in the 6th LRR of GPIbα. In this variant, mutated 
GPIbα cannot bind vWF, but thrombin binding is unaffected (13, 27). LRRs 2, 
3, and 4 of GPIbα are critical for vWF binding and platelet adhesion, and 
mutations within the LRRs 2, 5, 6, and 7 of GPIbα have been associated with 
BSS. Mutation of the three sulfated tyrosine residues strongly reduces vWF 
and thrombin binding (12). Deletion of Leu179 in the seventh LRR of GPIbα 
causes BSS (variant Nancy I) (8). A BSS variant with one amino acid 
substitution in the extracellular domain of GPIbβ affects maturation of GPIbα 
and GPIX stability (8).  
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GPV does not seem to be a cause of BSS as deficiency in its expression on 
platelets in mice does not affect platelet structure or size, or modify surface 
expression of GPIb or GPIX. No symptoms of BSS are present in the case of 
GPV deficiency (8).  
 
Heterozygous deficiency of GPIbβ has been linked to Di George syndrome or 
velo-cardio-facial syndrome, which are characterised by a micro deletion in 
22q11.2, an area where the GPIbβ gene maps to (8) Patients with the deletion 
tend to have macrothrombocytopenia, diminished ristocetin-induced 
aggregation, and reduced expression of the GPIB-IX-V complex (50). Patients 
with autoantibodies directed against GPIb have been demonstrated to 
develop immune thrombocytopenic purpura (38).
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Platelet Antagonists 
 
Platelets have a central role in atherosclerosis (involving plaque formation in 
inflamed blood vessels), myocardial infarction (MI; the cause of tissue death 
following occlusion of a coronary vessel by a thrombus), and other potentially 
fatal thrombotic disorders. Atherosclerotic plaques can rupture following 
platelet interactions, forming a platelet-rich thormbus which can occlude 
vessels in the heart or brain, causing MI or stroke respectively (1). 
 
The most commonly used anti-thrombotic drugs inhibit GPIIb/IIIa-mediated 
platelet aggregation, including fibrinogen receptor antagonists, acetylsalicylic 
acid (aspirin), and P2Y12 antagonists, for example clopidogrel. Recent clinical 
data with intravenous fibrinogen receptor antagonists and other anti-platelet 
drugs such as Prasugrel, demonstrated platelet inhibition and prevention of 
ischaemic complications, but were associated with increased bleeding 
complications. Inhibitors of GPIIb/IIIa are effective anti-thrombotic agents in 
acute situations, but can lead to thrombocytopenia and potentially life 
threatening bleeding complications, such as haemorrhages in the cerebral, 
alveolar, and gastrointestinal systems (15, 26). Furthermore, oral GPIIb/IIIa 
inhibitors enhanced cardiovascular events in clinical trials. Lower dosage of 
the oral inhibitors was used so that they could be used for chronic treatment 
to prevent thrombosis. However, lower dosage lead to less inhibition, along 
with low bioavailability of the drug. The GPIIb/IIIa antagonists induced 
conformational changes in the receptor, and also acted as partial agonists, 
causing an increase in platelet aggregation (15, 51).  
 
Aspirin effectively prevents thrombotic disorders, such as MI and stroke, by 
irreversibly inhibiting cyclooxygenase 1 (COX-1), an enzyme important in 
generating thromboxane A2, a potent platelet agonist (33). Thienopyridine 
anti-platelet drugs, including ticlopidine, prasugrel and clopidogrel, are pro-
drugs that block the P2Y12 ADP receptor, a receptor that normally augments 
platelet aggregation (33). Ticagrelor is an orally administered P2Y12 blocker, 
but is not a prodrug, meaning it does not require hepatic activation. Goto et al. 
showed that ticlopidine also prevented stabilization of vWF bound to GPIb 
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under high shear stress ex vivo, causing dissociation of thrombi (39). For 
long-term anti-platelet treatment, combined aspirin and clopidogrel treatment 
has limited side effects, but increased reports of treatment resistance 
emphasise the need for new anti-thrombotic agents. Aspirin resistance may 
be due to alterations in enzyme expression and regulation. Clopidogrel 
resistance may be caused by low rates of activation of the pro-drug to the 
active species due to genetics, blockage of, or competition for cytochrome 
P450 by food components or other medicines (40). It is likely that poor 
response to aspirin is due to inappropriate dosage. Weight is associated with 
reduced response to enteric-coated aspirin (52). 
 
Small molecule GPIIb/IIIa antagonists, including the monoclonal antibody 
abciximab (Reopro), the small molecule non-peptide inhibitor tirofiban, and 
eptifibatide (Integrillin), can reduce the incidence of acute thrombotic 
complications after coronary intervention by up to half. These agents block 
platelet aggregation and are used to prevent acute thrombotic complications 
after coronary intervention in patients with acute coronary syndromes and 
stable effort angina. However, abciximab has not been shown to have any 
extra benefit over dual treatment with aspirin and heparin in patients with 
acute coronary syndromes that did not undergo coronary intervention (33).  
 
Bleeding complications are the main and most serious side effects associated 
with GPIIb/IIIa antagonists. Coronary artery reocclusion is also a serious 
problem with many thrombolytic treatments. Monoclonal antibody treatment is 
not ideal as it could lead to immunogenicity, and it may not be reversible (25). 
There is demand for safe anti-platelet agents that can prevent or reduce 
thrombosis and atherosclerosis, while minimally affecting the normal 
haemostatic process, therefore preventing bleeding complications.  
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GPIb as an Anti-Thrombotic Agent 
 
There is great interest in targetting GPIb as an anti-thrombotic therapeutic as 
it is an easily accesible surface receptor restricted to platelets and has a 
major role in thrombotic diseases including MI and stroke (2, 9, 12). The 
interaction between GPIb and vWF initiates thrombus formation under high 
shear stress, unlike the GPIIb/IIIa interaction with fibrinogen which also takes 
place at lower shear rates found in the peripheral venous system. Inhibiting 
this interaction would be more effective in the arterial system compared to the 
venous system. This could possibly reduce bleeding complications compared 
to current anti-thrombotic agents such as aspirin (12, 41).  
 
GPIb has not been fully investigated as an anti-thrombotic mainly due to the 
differences between various species in the GPIbα receptor, making it difficult 
to test human blocking antibodies in small animal models. This problem did 
not occur with GPIIb/IIIa antagonists, which made the latter antagonists easier 
to develop (40).  
 
Several studies indicate that GPIb-IX-V complex inhibition would be an 
effective treatment for thrombosis. In patients with acute coronary syndromes, 
high shear stress induced platelet aggregation was increased when plasma 
vWF levels increased (41). Treatment of arteries with ferric chloride (FeCl3)
 
caused endothelial cells to detach from the sub-endothelium, exposing 
collagens, vWF and other sub-endothelial matrix proteins. In such models 
using non-human primates, inhibition of GPV, α2β1 (collagen receptor) or 
GPIbα reduced thrombus size with little effect on bleeding time (15). GPIb-IX-
V causes pathological arterial thrombosis upon binding to vWF exposed on 
the sub-endothelium after vascular damage. Blocking this interaction has 
been shown to reduce thrombus formation, and prevent long-term restenosis 
of narrowed vessels (9). It has been established that complete inhibition of 
GPIb by specific monoclonal antibodies in vivo in guinea pigs and baboons 
does not induce a haemorrhagic state (37, 38). 
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In vWF knockout mice, arterial thrombosis still occurs but complete vessel 
occlusion is either prevented or delayed. However, thrombus formation is 
completely inhibited in GPIb knockout mice, suggesting that GPIb receptor 
ligands, other than vWF, are important in platelet aggregation and thrombus 
formation (26). Inhibition of vWf and ADAMTS13 by monoclonal antibodies 
prevented thrombocytopenia and haemolytic anaemia in a baboon model of 
thrombotic thrombocytopenic purpura. However, partial inhibition of vWF was 
not effective (53). Since GPIb deficiency impairs thrombosis more effectively 
than vWF deficiency, GPIb is a more attractive target for antithrombotic 
therapy than vWF. There is a possibility that blocking vWF could affect its 
interaction with bound FVIII, which could affect the coagulation cascade. 
Targeting GPIb would not affect this interaction (26). 
 
No GPIb antagonists have been successfully used in clinical practice, 
although several potential candidates have been investigated (26, 41). VCL 
peptide (the A1 domain of vWF) inhibited platelet adhesion to vWF under 
static and shear conditions, and prevented thrombus formation in vivo (15). 
Specific proteases have been used to cleave GPIbα, leaving other platelet 
receptors intact. The two classes of proteases used are bacterial O-
sialylglycopeptide endopeptidases, which cleave GPIbα to liberate a 45 kDa 
fragment containing the ligand binding sites, and snake venom 
metalloproteases, which cleave GPIbα in the anionic peptide region to liberate 
a slightly smaller fragment. One such snake venom is mocarhagin. However 
there are some issues with using these proteases. Snake venom 
metalloproteases cleave GPIbα, but some can also affect other proteins such 
as vWF. Also, there is variability in cleavage completion depending on the 
donor and the platelet preparation (15).  
 
Antibodies to GPIbα, or their Fab fragments, effectively prevented thrombosis 
in non-human primates without causing bleeding complications. Kleinschnitz 
et al. showed that an anti-GPIbα antibody (Fab fragments) was more effective 
than depleting GPVI (the main signaling receptor for collagen) or than using 
an anti-GPIIb/IIIa antibody (Fab fragments) in a mouse middle cerebral, artery 
occlusion model, without increased bleeding complications (15).
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Snake Venoms 
 
Snake venoms contain many polypeptides and proteins that can alter 
thrombosis and haemostasis. The use of venoms as a therapeutic for 
thrombotic disorders has become an interesting option, as they could possibly 
alter the platelet response that can lead to cardiovascular and 
cerebrovascular pathology (31, 42).  
 
Snaclecs (snake venom C-type lectins) are a subset of non-enzymatic 
proteins isolated from snake venom, which include C-type lectins, and related 
proteins including C-type-like lectins and IX/X-bp like proteins. IX/X-bp like 
protein is a class of anticoagulant venoms, including two-chain botrocetin, 
convulxin, and mamushigin (42). The venoms of this class are heterodimers 
linked by an inter-subunit disulfide bond. The molecular weight of these 
proteins is approximately 30 kDa. N-terminal amino acid sequences in these 
proteins are highly conserved and extremely similar to C-type lectins. Despite 
their structural similarity, they all display different biological activities and 
mechanisms of action (31, 42).  
 
Snake venom C-type lectins and C-type-like lectins are important GPIb 
antagonists. They are widespread and found in nearly all Viperidae and 
Crotalidae, and some Elipidae, venoms. Most of these are part of the simple 
heterodimeric class, consisting of α- and β- subunits linked by swapping loops 
and a disulphide bridge (43).  
 
C-type-like lectins proteins are important haemorrhagic proteins derived from 
snake venom. Despite the similar structure of compounds within the class, 
their biological activity varies. They bind many diverse proteins including 
Factor IX, Factor X, GPIb, GPVI, CLEC-2 and α2β1 (45). Agkistin and 
rhodocetin are two C-type-like lectins. Agkistin blocks the vWF-GPIb 
interaction, and inhibits angiogenesis in vivo (44). Rhodocetin binds the 
collagen receptor α2β1, preventing collagen-induced platelet activation, similar 
to the effect of collagen-blocking antibodies (40). 
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C-type lectins form a large concave surface that is thought to bind to the outer 
domains of GPIbα, blocking binding to vWF, and in some cases thrombin 
(15). Some C-type lectins can bind to vWF, and GPVI (44). The C-type lectin 
jararhagin interacts with the α2β1. Some snake C-type lectins, for example 
echicetin, interact with the thrombin binding site on GPIbα, but have been 
shown to have no effect on the platelet response to thrombin, especially at 
low doses (< 0.5 U/ml) (4). Some of these proteins bind to more than one 
ligand, for example convulxin, alboaggregin A, and alboluxin all bind GPIbα 
and GPVI (44). Eptifibatide is a GPIIb/IIIa inhibitor based on barbourin, a 
disintegrin isolated from snake venom. It is a competitive inhibitor for 
fibrinogen in vivo (30). 
 
Snake venoms that bind GPIb can be agonists, for example botrocetin, or 
antagonists, such as echicetin purified from Echis carinatus (41). 
Crystallographic studies show that botrocetin, a snake venom often used to 
cause platelet aggregation in vitro, and bitiscetin, bind to both the 45 kDa 
outer domain of GPIbα and to the A1 domain of vWF, holding them together 
and enhancing their interaction. Therefore, molecules targeting GPIb may 
inhibit or activate platelets, depending on their mode of action (15).  
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Anfibatide 
 
Anfibatide is a novel GPIb antagonist purified from the compound 
agkisacutacin (26). Agkisacutacin is a large fibrinogenlytic C-type-like lectin 
containing α and β chains with interchain disulphide bonds. It has no Ca2+- or 
sugar- binding loops. It is derived from the tetrameric protein complex 
agglucetin, which is isolated from Agkistrodon acutus snake venom in the 
southern Anhui Province of China (31, 42).  
 
Agkisacutacin has two heterologous subunits linked by an intersubunit 
disulfide bond (42). It has a molecular weight of 29,500, with two heterodimers 
of 14 kDa (β-subunit with 27 residues) and 15.3 kDa (α-subunit with 31 
residues) (31, 42). Each subunit contains a compact lectin-like globular 
domain and long extended loop region (45). The N-terminal sequences of the 
two polypeptides of anfibatide hold more than 85% homology to that of the 
IX/X-bp family (31).  
  
Early studies using flow cytometry and competitive enzyme-linked 
immunosorbent assay (ELISA) demonstrated that agkisacutacin binds to GPIb 
and inhibits human vWF binding, while also binding to factor IX and factor X 
(44). The binding of the monoclonal antibody SZ 2 to GPIbα on platelets was 
blocked by agkisacutacin. Agkisacutacin did not block binding of the anti-
GPIIIa monoclonal antibody SZ 21 or the anti-GPIIb monoclonal antibody SZ 
22 to human platelets (44). After studying the crystal structure of the 
compound, it was suggested that each agkisacutacin αβ-heterodimer 
molecule binds to one GPIb molecule and inhibits the GPIb-vWF interaction 
without causing GPIb clustering, unlike flavocetin-A (26, 45). Flavocetin-A and 
echicetin are two C-type lectins with similar structures to anfibatide. They 
inhibit vWF-GPIb binding, and prevent platelet aggregation, but increase 
platelet agglutination by forming tetramers, or by binding to immunoglobulin 
Mκ (IgMκ) in the blood plasma, respectively (26, 45). 
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Agkisacutacin inhibited platelet adhesion and aggregation in vitro and in vivo, 
but did not cause platelet agglutination in plasma (45). In vivo in canines, 
agkisacutacin (0.9-3.6 µg/kg) significantly inhibited platelet aggregation (44). 
Agkisacutacin did not inhibit ADP- or collagen- induced PRP aggregation, and 
had little effect on thrombin induced aggregation (44). It significantly 
prolonged clotting time, prothrombin time and activated partial thromboplastin 
time, and showed dose-dependent anticoagulation ex vivo in human blood 
(44). Agkisacutacin did not cause significant platelet activation (as measured 
by P-selectin expression and GPIIb/IIIa activation) ex vivo, prolong tail-
bleeding time in vivo, or cause spontaneous bleeding in mice (26). 
Agkisacutacin was shown to be stable at -70°C for up to 46 days (41). 
 
Agkisacutacin had a linear relationship between protein concentrations and 
fibrinolytic activity, significantly and directly reducing plasma levels of 
fibrinogen in a dose-dependent manner. It cleaved the fibrinogen α-chain and 
β-chain slowly, with little γ-chain cleavage, producing polypeptides of 
molecular weight 43 kDa, 40 kDa, 36 kDa, and 23 kDa. Lysis of the fibrinogen 
α-chain caused fibrinogen clotting ex vivo (26, 42). Agkisacutacin had a 
different cleavage site on fibrinogen than thrombin or plasmin. Unlike other 
fibrinolytic venom metalloproteases, agkisacutacin cleaves fibrinogen at a 
specific site, with little haemorrhagic or anti-coagulant activity (42). It is 
unknown why agkisacutacin could have fibrinolytic activity along with 
inhibitory effects on platelet aggregation in vitro and in vivo. The 
fibrinopeptides, containing RGD sequence, that result from fibrinogen 
cleavage may competitively inhibit fibrinogen binding to GPIIb/IIIa, thereby 
inhibiting platelet aggregation. In rats, agkisacutacin can significantly 
accelerate the lysis of pulmonary emboli, suggesting fibrin digestion either 
directly or indirectly, or both (31). When agkisacutacin was further purified by 
three-step chromatography to form anfibatide, all fibrinogenlytic activity was 
lost (44). 
 
 33 
Agkisacutacin was used in ten healthy Chinese volunteers to assess its 
pharmacokinetics. Agkisacutacin protein was dissolved in sterile normal saline 
for intravenous bolus administration at a concentration of 5 µg / 60 kg. The 
peak time for agkisacutacin concentration in plasma was eight hours and the 
terminal half-life was 10.5 hours. No antibodies to agkisacutacin were formed 
in the volunteers, and there were no changes in haematological or 
coagulation parameters. Bleeding time was not significantly prolonged (41).  
 
Anfibatide, the purified form of agkisacutacin, inhibited ristocetin-induced 
aggregation in washed murine platelets with recombinant murine vWF (26, 
44). It blocked botrocetin-induced binding of vWF from murine plasma to 
recombinant human GPIbα as measured by ELISA. It did not inhibit 
botrocetin-induced aggregation in murine PRP. Anfibatide inhibited ristocetin-
induced, but not botrocetin-induced, aggregation using human PRP, indicating 
a different binding site than other snake venom-derived GPIb antagonists. In 
an ongoing clinical trial, anfibatide inhibited ristocetin-induced aggregation in 
human PRP, confirming the difference in tertiary interactions between 
anfibatide, and human and mouse GPIb. In a rat arterio-venous shunt model 
anfibatide significantly inhibited thrombus formation in a dose-dependent 
manner (26). 
Anfibatide strongly inhibited platelet adhesion, aggregation, and thrombus 
formation in perfusion chambers, at high shear rates (1,800 s-1), and 
dissolved preformed thrombi ex vivo. Anfibatide inhibited thrombus formation 
at low shear rates (300 s-1), though less than at high shear rates. As shear 
stress increased incrementally from 100 s-1 to 5,000 s-1 in perfusion 
chambers, inhibition of thrombus formation by anfibatide increased. The 
inhibition was approximately 100 times stronger at high shear (1,800 s-1) 
compared to low shear (300 s-1). In anfibatide-treated platelets at 5,000 s-1, 
adhesion and aggregation on collagen was undetectable (26). Anfibatide may 
interact with other plasma proteins that favour thrombolysis, possibly 
explaining how anfibatide induces thrombus dissolution ex vivo (26).  
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Anfibatide markedly inhibited thrombosis in laser-injured cremaster vessels 
and prevented vessel occlusion in FeCl3-injured mesenteric vessels in mice. 
In anfibatide-treated mice, thrombus formation was delayed, unstable, easily 
dissolved, and not occlusive. In vWF-deficient mice that had impaired laser-
induced thrombosis compared to wild-type (WT) mice, anfibatide inhibited 
thrombus formation further than knockout alone. This suggests that anfibatide 
inhibits thrombotic pathways mediated by GPIbα, aside from the GPIb-vWF 
interaction (26).  
 
Lee’s Pharmaceutical Limited is currently recruiting participants in China for a 
phase Ib-IIa clinical trial. The trial will investigate the safety and efficacy of 
anfibatide in non-ST segment myocardial infarction patients. It is a multi-
center, randomised, double-blind, placebo-controlled trial. The primary 
outcome measure is thrombosis formation 48 hours after infusion during stent 
implantation. Secondary outcome measures are mortality (30 days after 
treatment), bleeding events and thrompbocytopenia. The study is due to finish 
in February 2015 and it is hoped that 90 patients will participate. A bolus 
injection with different doses of anfibatide will be administered immediately 
when the guidewire passes through the first stenosed vessel, along with an 
intravenous infusion at 0.002 IU/kg/h for 48 hours afterwards. Saline will be 
used as a placebo. The study aims to establish the efficacy of different doses 
of anfibatide so that Phase III trials can progress. The study will accept males 
or females aged between 18 and 70 years. Patients must show an increase in 
markers of myocardial damage, ischaemic symptoms, and must give informed 
consent (46). Phase I Clinical trials were completed in March 2011. Anfibatide 
was administered to 94 healthy volunteers. The primary outcome measure 
was the number of adverse events in patients with single or multiple 
intravenous injections or infusions. The secondary outcome measure was the 
observation of area under curve characteristics of anfibatide in single or 
multiple dose groups. A dose of 0.33 – 5 µg/60 kg was administered in a  
single dose (47). The Phase I trial demonstrated that anfibatide did not 
significantly decrease platelet count or prolong bleeding time. There were no 
serious adverse events or deaths during the study, and all results indicated 
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that anfibatide is a safe and potent anti-platelet reagent, and a potential anti-
thrombotic therapy (48).
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Bacterial-Platelet Interactions 
 
A major cause of MI, stroke, and other conditions involving dysregulated 
platelet function, is pathogenic bacteria circulating in the blood. Many strains 
of bacteria can cause platelet activation, aggregation, and thrombocytopenia. 
Staphylococcus aureus is the most common cause of infective endocarditis, 
and acts through GPIIb/IIIa. Streptococcus sanguinis and streptococcus 
gordonii act through the GPIb receptor, at the N-terminal (1-225 residues) of 
GPIbα, to cause direct platelet aggregation. The ability of S. sanguinis to 
adhere to and to activate platelets corresponds to disease severity. GPIb 
interacts with a glycoprotein, serine-rich protein A (SrpA) on S. sanguinis to 
cause strong adhesion and rapid platelet aggregation. Anti-GPIb antibodies 
can inhibit the aggregation response to S. sanguinis. S. gordonii binds GPIb 
through the surface-anchored GspB to stimulate platelet activation. 
Heliobacter pylori strains also interact with GPIb, as indicated when anti-GPIb 
antibodies prevented platelet aggregation in its presence (1). In this study we 
investigate the effect of anfibatide on S. sanguinis-induced platelet 
aggregation, in order to determine if it would be useful as a therapeutic agent 
in treating or preventing bacterial-induced cardiovascular events.
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The Assay 
 
As anfibatide progresses through clinical trials, it is necessary to develop a 
tool to accurately measure the exact occupancy of GPIb receptors by 
anfibatide. An assay that measures receptor occupancy needs to be simple to 
learn, and accessible in hospital laboratories so that it can be widely used 
wherever patients are being treated. By measuring receptor occupancy of 
anfibatide, clinicians can precisely control dosage of the drug, thereby 
providing optimal therapeutic benefit, while limiting side effects. 
 
There are three main approaches to measuring drug levels in patients: 
measuring plasma levels of the drug, measuring receptor binding, or 
functional analysis. Measuring plasma levels of drugs is not always accurate, 
particularly in the case of drugs that have high affinity binding to their 
receptor. For example, even when aspirin levels are low, antiplatelet effects 
are still seen as the drug is bound to platelets rather than circulating in the 
plasma (54). Functional analysis for anti-platelet agents generally involves 
measuring platelet aggregation. This involves isolating PRP from patient 
blood samples, and the assay may be long and difficult. Furthermore, most 
hospitals do not have access to platelet aggregometers, and the majority of 
health professionals are not trained in the technique. There is also wide 
variation in the results obtained from different platelet functional tests (24). 
Receptor binding is usually difficult to measure due to the tissue where 
receptors are present being inaccessible. This is not the case with anti-
platelet agents, as platelets are easily accessible in the blood. The receptor 
occupancy method has previously been used to evaluate binding of abciximab 
to GPIIb/IIIa (55). 
 
We have developed a novel GPIb receptor occupancy assay based on a 
GPIIb/IIIa receptor occupancy assay previously developed in this lab (55). A 
platelet calibrator kit, marketed by Biocytex, was used. The kit is normally 
used to measure platelet glycoprotein expression levels. We have optimised 
the assay using GPIb monoclonal antibodies. This assay is accessible to any 
clinician who has access to a flow cytometer. The development of this assay 
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is particularly important when studying the pharmacokinetics of anfibatide in 
Phase Ib-IIa trials. It will help clinicians assess the receptor occupancy of 
anfibatide, and therefore it could be used to help determine the appropriate 
dose in patients based on these trials.
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Aims 
 
1. To develop a quantitaive flow cytometry based receptor occupancy 
assay for the novel GPIb receptor antagonist anfibatide. 
2. To validate this assay in healthy donor platelets ex vivo. 
3. To use this assay to investigate the efficacy of Anfibatide in healthy 
donor blood ex vivo. 
4. To investigate the effect of Anfibatide on S. sanguinis induced platelet 
aggregation ex vivo. 
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Chapter 2: Materials and Methods 
Materials 
Materials used are summarised in table 2.1 below. 
 
Table 2.1: Summary table of materials and suppliers 
Anti-anfibatide antibody 1B9 
Anfibatide 
Lee’s Pharmaceutical Limited, Hong 
Kong 
PLATELET calibrator kit 
PLATELET GPIIb/IIIa Occupancy kit 
CD42b clone ALMA 19 
CD42b clone SZ 2 
Biocytex, Marseilles, France 
CD62P (P-selectin), PE format BD Biosciences, Oxford, UK 
Round bottom FACS test tubes VWR International Ltd, Dublin, Ireland 
Sodium Citrate 
Brain Heart Infusion (BHI) Broth 
BHI Agar 
Phosphate buffered saline (PBS) 
All other reagents 
Sigma Aldrich Ireland Limited, Co. 
Wicklow, Ireland 
 
Adenosine di-phosphate (ADP) 
Arachidonic acid 
AggRecetin (ristocetin) 
Aggregation test tubes 
Micro-magnetic stir bars 
Bio/data Corp, PA, USA 
Multiplate test cells Roche Diagnostics, West Sussex, UK 
VM16d anti-CD42b antibody Abcam, Cambridge, UK 
Mouse anti-human monoclonal 
antibody, IgG2a isotype, AN51 
Fischer Scientific Ireland, Dublin, 
Ireland 
S. aureus Newman Gift from Prof. Timothy J Foster, TCD 
S. sanguinis NCTC 7863 National Collection of Type Cultures, 
UK 
S. sanguinis 133-79 Gift from Dr. Mark Herzburg 
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Methods 
1. Preparation of Blood 
Whole blood was collected in 3.8% sterile sodium citrate, in the ratio 9:1, from 
healthy volunteers who had abstained from using anti-platelet agents in the 
previous 10 days. This study was approved by the RCSI Research Ethics 
Committee, approval number REC676. To prepare platelet rich plasma (PRP), 
whole blood was aliquoted and centrifuged at 150 rpm for 10 minutes. PRP 
was collected. To prepare platelet poor plasma (PPP), 1 ml of PRP was 
centrifged for a further 5 minutes. PPP was collected and the platelet pellet 
was discarded. 
 
2. Quantitative Flow Cytometry  
Quantitative flow cytometry was performed using a BD FACS Canto II flow 
cytometer (Becton Dickinson, UK). A platelet calibrator kit (Biocytex, France) 
was used, and the accompanying instructions were followed. Briefly, platelets 
were stained with specific monoclonal antibodies by no wash indirect 
immunofluorescence. Whole blood (10 µl) was diluted 1:10 with diluent from 
the kit. Diluted samples were incubated with either a negative control from the 
kit, or a specific chosen antibody at a final concentration of 10 µg/ml for 20 
minutes at room temperature. Anti-mouse IgG-FITC (10 µl) was added for 10 
minutes. This antibody was previously optimised and provided in the kit. 
Beads coated with an increasing and specifically known amount of mouse IgG 
were labelled with IgG-FITC for 10 minutes, and used to create a calibration 
curve. The samples were then diluted with 1 ml of diluent from the kit. The 
samples were analysed using quantitative flow cytometry. Platelets were 
gated, 10,000 events were recorded, and the FITC-A geomean was used for 
analysis. 
 
3. 1B9 Concentration Optimisation 
A mouse monoclonal anti-anfibatide antibody, 1B9, was developed in China 
(41). The optimal concentration of anti-anfibatide antibody 1B9 to be used in 
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the development of this assay was determined using quantitative flow 
cytometry. Serial dilutions of 1B9 were made using tris buffered saline (TBS; 
50 mM Tris-Cl, 150 mM NaCl, pH 7.5). Whole blood was incubated with 
anfibatide (final concentration of 6.24 µg/ml) for 30 minutes at room 
temperature. Of each dilution of 1B9, 10 µl was incubated at room 
temperature for 20 minutes with 10 µl of anfibatide-treated whole blood. 
Mouse anti-IgG FITC (10 µl) was added for 10 minutes at room temperature. 
The sample was diluted using 1 ml diluent from the platelet calibrator kit 
(Biocytex, France). The sample was analysed using quantitative flow 
cytometry on a FACS machine as described above. 
 
4. Flow Cytometry based Dose Response of Anfibatide in Whole Blood 
A platelet calibrator kit (Biocytex, France) was used to determine the optimal 
concentration of anfibatide that causes maximum binding to platelets. 
Platelets in whole blood were stained by no wash indirect 
immunofluorescence with the optimal dose of 1B9, as determined previously 
in section 3. Whole blood was incubated with varying doses of anfibatide at 
room temperature for 30 minutes. Each sample was diluted 1:10 with diluent 
from the kit. Diluted whole blood (10 µl) was labelled with 10 µl of 1B9 (final 
concentration: 3.68 µg/ml) for 20 minutes at room temperature. Mouse anti-
IgG FITC was added (10 µl) for 10 minutes at room temperature. Sample was 
then diluted using 1 ml diluent from the kit, and analysed as described in 
section 2. 
 
5. Effect of Anfibatide on Various Anti-GPIb Monoclonal Antibodies 
Anfibatide treated whole blood was incubated with various anti-GPIb 
monoclonal antibodies (AN51, SZ 2, VM16d, ALMA 19, and WM23) at a final 
concentration of 10 µg/ml, and protocol was carried out as described in 
section 2. 
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6. Effect of Anfibatide on Anti-GPIIb/IIIa Monoclonal Antibodies  
A platelet GPIIb/IIIa occupancy kit (Biocytex, France) was used to determine 
the effect of anfibatide on GPIIb/IIIa. Whole blood was incubated with 
anfibatide (final concentration: 10 µg/ml) for 30 minutes at room temperature. 
Anfibatide-treated, and control whole blood was incubated with MAb1 and 
MAb2, two anti-GPIIb/IIIa antibodies provided in the kit. Protocol as described 
in section 2. 
 
7. Platelet Activation by Anfibatide 
Whole blood was incubated varying concentrations of anfibatide at room 
temperature for 30 minutes. This whole blood (10 µl) was added to 10 µl 
CD62-PE for 10 minutes. Whole blood incubated with 20 µM thrombin 
receptor activating peptide (TRAP) acted as a positive control. Each sample 
was diluted with 1 ml PBS, and analysed using a FACS machine. PE 
geomean was recorded and used for analysis. 
 
8. Loss of Single Platelets in PRP  
PRP was prepared as described in section 1. PRP was incubated with various 
concentrations of anfibatide for 30 minutes at room temperature. Platelet 
count was measured using a Sysmex haematology analyser (Kobe, Japan). 
 
9. Effect of Anfibatide on Whole Blood Aggregation and PRP Aggregation 
Induced by S. aureus Newman and S. sanguinis 133-79 
S. aureus Newman, and S. sanguinis 133-79 bacterial strains were grown 
overnight in brain heart infusion (BHI) broth at 37°C . Innoculated broth was 
centrifuged at 5,000 rpm for 10 minutes. Broth was removed and the bacterial 
pellet was resuspended in 50 ml sterile PBS. The bacterial solution was 
centrifuged at the same settings again. PBS was removed and the final pellet 
was resuspended in 1 ml PBS. Bacteria was adjust to an optical density 
(OD600) of 1.6 using an Ultraspec III spectrophotometer (Pharmacia Biotech, 
UK).  
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For whole blood aggregometry, a Multiplate analyser (Roche Diagnostics, UK) 
was used. The Multiplate test cell consists of two sensors onto which platelets 
can adhere and aggregate when activated by an appropriate agonist. This 
adhesion and aggregation causes an increase in impedance, which is then 
recorded in arbitrary aggregation units and plotted against time on the 
analyser. The area under the aggregation curve (AUC) is the commonly used 
parameter. This takes the total height of the aggregation curve, and the slope 
of the curve, into account. Whole blood was incubated with 32 µg/ml 
Anfibatide at room temperature for 30 minutes. Anfibatide-treated whole blood 
(300 µl) was diluted with 300 µl PBS and allowed to rest at 37°C for 5 minutes 
in a Multiplate test cell. Bacteria (1:10) was added to the test cell and 
aggregation was recorded for 20 minutes. All aggregations took place in the 
Multiplate analyser (Roche Diagnostics, UK), at 37°C, and samples were 
mixed using disposable magnetic stir bars. Anti-GPIb antibody AN51, at a 
final concentration of 12.5 µg/ml, was incubated with whole blood for 10 
minutes, prior to aggregation. 
 
For PRP aggregation, PRP and PPP were both isolated as outlined in section 
1. A PAP-8 platelet aggregometer (Biodata, USA) was used to carry out light 
transmission aggregometry. PRP was incubated with anfibatide for 30 
minutes at room temperature. PPP (250 µl) was used to blank the machine. 
Bacteria was then added to PRP (1:10 dilution) and aggregation was 
measured for 30 minutes. Magnetic stir bars were used to mix the samples 
druing aggregation, and all aggregations took place at 37°C. 
 
10. The Effect of Anfibatide on Ristocetin Induced Whole Blood Aggregation 
A dose response to ristocetin in a healthy volunteer using a Multiplate 
analyser found that 0.5 mg/ml ristocetin was the minimum dose of ristocetin to 
induce aggregation in whole blood. Following this, whole blood was incubated 
with various doses of anfibatide for 30 minutes at room temperature. 
Aggregations were carried out as described in section 8, inducing aggregation 
by adding ristocetin at a final concentration of 0.5 mg/ml. 
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11. Effect of Anfibatide on Aggregation in PRP Induced by Various Agonists 
PRP was incubated with anfibatide at a final concentration of 10 µg/ml for 30 
minutes at room temperature. Various agonists were added to PRP and 
aggregation was recorded using light transmission aggregometry (LTA) with a 
PAP-8 platelet aggregometer for 10 minutes. Agonists included low dose 
thrombin (0.05 U/ml), high dose thrombin (0.5 U/ml), ADP, arachidonic acid 
and ristocetin (1 mg/ml). 
 
12. Statistical Analysis 
Results were analysed using ANOVA and Student’s T-test, paired and 
unpaired. Data was considered statistically significant when p<0.05. 
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Chapter 3: Results 
 
3.1. 1B9 optimisation 
 
In order to develop an assay to measure the occupancy of the GPIb receptor 
on platelets by the novel drug anfibatide, an antibody directed against 
anfibatide was developed in China and named 1B9. The optimal 
concentration of 1B9 to be used, that is the concentration of 1B9 that 
maximally detects anfibatide binding, was determined using quantitative flow 
cytometry. A high dose of 10 µg/ml anfibatide was chosen from previous 
literature (26). Whole blood was labelled with various concentrations of 1B9, 
and the optimal dose was determined to be 3.68 µg/ml. At this concentration, 
54,784 ± 7,592 molecules of anfibatide were detected. As 1B9 concentration 
increased past this point, binding to anfibatide decreased (Figure 3.1.1). 
 
 
Figure 3.1.1. The optimum concentration of anti-anfibatide antibody 1B9 that detects 10 
µg/ml anfibatide, in whole blood, using quantitative flow cytometry, is 3.68 µg/ml. 
Number of anfibatide molecules bound to platelets as measured by various doses of anti-
anfibatide antibody 1B9 in whole blood samples from healthy donors using quantitative flow 
cytometry, n=3-4, error bars represent SEM. 
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3.2. Anfibatide dose response 
 
Following the determination of the optimal dose of 1B9 (3.68 µg/ml) to be 
used in this assay, binding of anfibatide to healthy donor platelets was 
measured. Various doses of anfibatide were incubated with whole blood for 
30 minutes at room temperature. In this dose response, maximal binding was 
detected at 16 µg/ml, showing 69,181 ± 6,242 binding sites per platelet 
(Figure 3.2.1). 
 
Figure 3.2.1. Anfibatide dose response, using quantitative flow cytometry, with whole 
blood and 3.68 µg/ml anti-anfibatide antibody 1B9. Number of anfibatide molecules bound 
to platelets varying with dose, as measured using quantitative flow cytometry, with anti-
anfibatide antibody 1B9 (3.68 µg/ml) in whole blood samples from healthy donors, n=3, error 
bars represent SEM.  
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The results from figure 3.1.1 suggested that the optimal concentration for 1B9 
use was 3.68 µg/ml, after which detection decreased. In order to ensure that 
this was the optimum dose of 1B9, 3.68 µg/ml and a higher dose of 7.35 
µg/ml were tested against a range of Anfibatide concentrations. At 3.68 µg/ml, 
1B9 detects significantly more binding sites at high doses of anfibatide 
compared to 7.35 µg/ml 1B9, p=0.016 (Figure 3.2.2). 
 
 
 
Figure 3.2.2. 3.68 µg/ml 1B9 detects more binding sites to anfibatide than 7.35 µg/ml 
1B9, as measured using flow cytometry. Number of anfibatide molecules bound to 
platelets varying with dose, using quantitative flow cytometry, comparing 3.68 µg/ml 1B9 and 
7.35 µg/ml 1B9 in whole blood samples form healthy donors, n=3. There is a significant 
decrease in receptor numbers detected by 1B9 at 7.35 µg/ml compared to 3.68 µg/ml, 
p=0.016, paired t-test, error bars represent SEM. 
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3.3. Effect of anfibatide on anti-GPIb monoclonal antibodies 
 
An anti-GPIb antibody that is not inhibited by anfibatide is required to measure 
total GPIb receptor numbers per platelet. The effect of anfibatide on binding of 
five anti-GPIb antibodies to platelets was measured using quantitative flow 
cytometry. These monoclonal antibodies were also used to determine the 
binding site of the drug. All antibodies were used at a final concentration of 10 
µg/ml. Each anti-GPIb antibody showed a different number of binding sites 
per platelet (Figure 3.3.1). AN51 had the lowest number of binding sites 
(14,325 ± 1,949 binding sites), ALMA 19, SZ 2, and WM23 detected between 
27,000 and 33,000 receptors, and VM16d had 40,880 ± 8,931 binding sites. 
There was a significant difference between GPIb receptor numbers as 
measured by AN51 compared to WM23, SZ 2, and ALMA 19 (p<0.05). 
 
 
Figure 3.3.1. GPIb receptor numbers vary depending on the anti-GPIb monoclonal 
antibodies used in quantitative flow cytometry. Whole blood was labelled with various 
anti-GPIb monoclonal antibodies and receptor numbers were measured using quantitative 
flow cytometry. All antibodies were used at a final concentration of 10 µg/ml. There was a 
significant difference in receptor numbers as measured by AN51 compared to WM23, SZ 2, 
and ALMA 19, p<0.05, multiple paired t-tests, error bars represent SEM. 
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Binding of WM23, AN51, and ALMA 19 antibodies was not significantly 
affected by anfibatide (p>0.7). Binding of VM16d was inhibited by 52 ± 2% by 
10 µg/ml anfibatide pre-incubated with whole blood for 30 minutes at room 
temperature, p=0.036. SZ 2 was inhibited 23 ± 1% by 10 µg/ml Anfibatide, 
p=0.012 (Figure 3.3.2).  
 
Figure 3.3.2. Anfibatide partially inhibits VM16d and SZ 2 at 10 µg/ml. Whole blood was 
incubated with various doses of anfibatide for 30 minutes. Binding of five anti-GPIb antibodies 
(VM16d, SZ 2, ALMA 19, AN51, and WM23) to healthy donor platelets was measured using 
quantitative flow cytometry. Binding of two antibodies was significantly inhibited by anfibatide 
compared to the control group which was not incubated with anfibatide: VM16d, p=0.036, and 
SZ 2, p=0.012, one-way ANOVA, error bars represent SEM, n=3.
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The effect of anfibatide on high dose VM16d (20 µg/ml) was also tested 
(Figure 3.3.3). Anfibatide did not significantly inhibit VM16d at 20 µg/ml 
binding in the presence of 10 µg/ml anfibatide (p>0.05). VM16d at 10 ug/ml 
was partially inhibited by 10 µg/ml anfibatide (p=0.0123). 
 
 
Figure 3.3.3. High dose VM16d (20 µg/ml) is not inhibited by anfibatide. Anfibatide was 
incubated with whole blood for 30 minutes at room temperature. Binding to 20 µg/ml and 10 
µg/ml VM16d was measured using quantitative flow cytometry and compared to the control 
blood samples, which had not been incubated with anfibatide. No significant inhibition of 
binding was detected with 20 µg/ml VM16d, p>0.05. VM16d at 10 µg/ml was significantly 
inhibited by 10 µg/ml anfibatide, p=0.0123, paired t-test, n=3-6, error bars represent SEM. 
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GPIb receptor numbers were measured using VM16d at 20 µg/ml, and 1B9 at 
7.35 µg/ml directed against two doses of anfibatide. Both antibodies gave 
similar receptor numbers (40,000 – 50,000 binding sites) and were not 
inhibited by increasing anfibatide dosage (p>0.3). 
 
Figure 3.3.4. Number of GPIb receptors detected, by quantitative flow cytometry, on 
platelets by VM16d and 1B9 are not statistically different following incubation of whole 
blood with anfibatide. Whole blood was incubated with two doses of anfibatide for 30 
minutes at room temperature. GPIb receptor binding was detected using quantitative flow 
cytometry. VM16d (20 µg/ml) and 1B9 (7.35 µg/ml) were used. Control samples were not 
incubated with anfibatide. There was no significant difference between receptor numbers 
when incubated with 16 µg/ml, or 51 µg/ml anfibatide, as detected by VM16d, and 1B9, p>0.3, 
two-way ANOVA and multiple t-tests, n=3, error bars represent SEM. 
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3.4. Effect of anfibatide on anti-GPIIb/IIIa monoclonal antibodies 
 
The effect of anfibatide on binding of monoclonal antibodies directed against 
the GPIIb/IIIa receptor was examined to confirm that GPIIb/IIIa was not the 
binding site of anfibatide. Anfibatide at a final concentration of 10 µg/ml did 
not inhibit binding of two monoclonal antibodies, MAb1 and MAb2, as 
measured by quantitative flow cytometry (p>0.999). Both antibodies were 
from the GPIIb/IIIa receptor occupancy kit (Biocytex, France). 
 
 
Figure 3.4.1. Anti-GPIIb/IIIa monoclonal antibodies, MAb1 and MAb2 (Biocytex, France), 
are not affected by anfibatide. Anfibatide does not significantly affect binding of the anti-
GPIIb/IIIa monoclonal antibodies, MAb1 and MAb2 in whole blood samples using flow 
cytometry, compared to control samples which were not incubated with anfibatide, n=3, 
p=>0.999, paired t-test, error bars represent SEM. 
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3.5. Effect of anfibatide on platelet activation 
 
The effect of anfibatide on platelet activation was measured using quantitative 
flow cytometry. Platelet activation was quantified by measuring CD62 (P-
selectin) levels on the platelet surface. CD62 is released from α-granules in 
platelets and displayed on the cell surface following activation, for example by 
TRAP. TRAP activated platelets were used as a positive control to measure 
CD62 expression. Anfibatide at 6 µg/ml, and 25.5 µg/ml, did not cause platelet 
activation after incubation for 30 minutes at room temperature. 
 
 
Figure 3.5.1. Anfibatide does not activate platelets (CD62P) as measured by flow 
cytometry in whole blood. Measurement of platelet activation by anfibatide as measured by 
CD62 levels using flow cytometry. Anfibatide did not cause platelet activation compared to 
control sample incubated with 20 µM TRAP in whole blood samples from healthy donors, 
n=3, error bars represent SEM.
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3.6. Loss of single platelets following anfibatide treatment 
 
The effect of Anfibatide on platelets was examined using a loss of single 
platelets study. Following incubation with anfibatide for 30 minutes at room 
temperature, platelet count was measured using a Sysmex haematology 
analyser. Recorded platelet numbers did not significantly differ following 
anfibatide treatment (p=0.27) indicating that anfibatide does not cause a loss 
of single platelets in vitro (figure 3.6.1). 
 
 
Figure 3.6.1. Anfibatide does not cause a loss of single platelets. Various concentrations 
of anfibatide do not cause a decrease in the average number of platelets in PRP samples 
incubated with anfibatide at room temperature for 30 minutes, compared to a sample that was 
not incubated with anfibatide, p=0.27, ANOVA, n=3, error bars represent SEM. 
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3.7. The effect of anfibatide on ristocetin-induced platelet aggregation in 
whole blood 
 
Ristocetin was used to induce platelet aggregation in whole blood, and the 
effect of anfibatide on this aggregation was examined. Anfibatide inhibited 
ristocetin-induced aggregation in whole blood in a dose dependent manner 
(p=0.043). On average, a dose of 10 µg/ml anfibatide inhibited aggregation by 
77.5% (figure 3.7.1). IC50 is 2.39, 95% CI 1.08 – 5.31, R2=0.84.  
 
 
Figure 3.7.1. Anfibatide inhibits whole blood aggregation induced by 0.5 mg/ml 
ristocetin in a dose dependent manner. Anfibatide inhibited whole blood aggregation 
induced by 0.5 mg/ml ristocetin in a dose dependent manner, compared to aggregation 
occuring in the absence of anfibtide, as measured using a Multiplate analyser, n=3, p=0.043, 
ANOVA, error bars represent SEM.  
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3.8. The effect of anfibatide on ristocetin-induced platelet aggregation in PRP 
 
The effect of anfibatide on platelet aggregation induced by 1 mg/ml ristocetin 
in PRP was measured using a PAP-8 aggregometer. Anfibatide significantly 
inhibited platelet aggregation in a dose dependent manner (p=0.019). 
Anfibatide at a final concentration of 5 µg/ml inhibited aggregation by 94 ± 4% 
(figure 3.8.1). 
 
 
Figure 3.8.1. Anfibatide inhibits ristocetin induced aggregation in PRP in a dose 
dependent manner. Anfibatide inhibited aggregation induced by 1 mg/ml ristocetin in PRP as 
measured by light transmission aggregometry. The inhibition was dose dependent, p=0.092, 
ANOVA, n=3-4, error bars represent SEM.  
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3.9. GPIb receptor occupancy compared to inhibition of ristocetin-induced 
aggregation in whole blood by anfibatide 
 
As shown in figure 3.3.4, 20 µg/ml VM16d detects a similar number of binding 
sites to high dose anfibatide. VM16d was used to measure total GPIb receptor 
numbers. A flow cytometry based dose response to anfibatide was carried out 
using 7.35 µg/ml 1B9. Each dose was compared to the total receptor number 
as measured by VM16d and receptor occupancy was measured as a 
percentage. On the same day, using the same healthy donor whole blood 
samples, a dose response of ristocetin-induced platelet agregation to 
anfibatide was carried out. The inhibition of aggregation was expressed as a 
percentage and plotted with receptor occupancy as measured by VM16d 
(figure 3.9.1). Inhibition matched of aggregation closely matched GPIb 
receptor occupancy by anfibatide in each donor. IC50 for receptor occupancy 
is 5.295, and 95% CI is 1.96 – 14.29. IC50 for inhibition of aggregation is 4.33. 
95% CI is 1.43 – 13.14. R2 = 0.97, 0.95 respectively. 
   
 
Figure 3.9.1. Receptor occupancy by anfibatide correlates with inhibition of whole 
blood aggregation by anfibatide. Total GPIb receptor number is measured using 20 µg/ml 
VM16d, and GPIb receptor occupancy by anfibatide is measured with 7.35 µg/ml anti-
anfibatide antibody 1B9, using quantitative flow cytometry. This is compared to the inhibition 
of aggregation induced by 0.5 mg/ml ristocetin in whole blood samples incubated with varying 
doses of anfibatide for 30 minutes at room temperature, n=3, error bars represent SEM.
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Receptor occupancy was also measured using a lower doses of VM16d (10 
µg/ml), and 1B9 (3.675 µg/ml), and compared to inhibition of aggregation by 
anfibatide at 0.02 µg/ml and 10 µg/ml (figure 3.9.2). Receptor occupancy and 
inhibition of aggregation also matched at these concentrations. 
 
 
 
Figure 3.9.2. GPIb receptor occupancy by anfibatide correlated with inhibition of 
ristocetin-induced whole blood aggregation by anfibatide. Total GPIb receptor number is 
measured using 10 µg/ml VM16d, and GPIb receptor occupancy by anfibatide is measured 
using 3.675 µg/ml anti-anfibatide antibody 1B9. This is compared to the inhibition of 
aggregation induced by 0.5 mg/ml ristocetin in whole blood samples incubated with varying 
doses of anfibatide for 30 minutes at room temperature, n=3, error bars represent SEM. 
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3.10. The effect of Anfibatide on aggregation induced by various agonists 
 
The effect of high dose anfibatide (10 µg/ml) on platelet aggregation induced 
by various agonists in PRP was tested using a PAP-8 platelet aggregometer. 
Anfibatide did not significantly affect aggregation induced by high dose 
thrombin, low dose thrombin, ADP or arachidonic acd. Anfibatide fully 
inhibited aggregation induced by 1 mg/ml ristocetin (p=0.0002). 
 
 
Figure 3.10.1. 10 µg/ml anfibatide does not effect aggregation induced by high dose or 
low dose thrombin, ADP or arachidonic acid in PRP, but does inhibit ristocetin induced 
aggregation, as measured by light transmission aggregometry. Anfibatide did not 
significantly affect aggregation induced in PRP by low dose thrombin (0.05 U/ml), high dose 
thrombin (0.5 U/ml), ADP, or arachidonic acid, compared to control samples that were not 
incubated with anfibatide. Anfibatide completely inhibits ristocetin-induced aggregation in 
PRP, p=0.0002, multiple paired t-tests, n=3-5, error bars represent SEM. 
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3.11. The effect of anfibatide on bacteria-induced platelet aggregation in 
whole blood  
 
Two bacteria strains were used to induce platelet aggregation in whole blood 
samples from healthy donors: Staphylococcus aureus Newman, and 
Streptococcus sanguinis 133-79. S. aureus Newman causes platelet 
aggregation by interacting with the FcγRIIa receptor and GPIIb/IIIa. Since 
anfibatide does not interact with GPIIb-IIIa as measured by a monoclonal 
antibody study (figure 3.4.1), it is expected to have no effect on S. aureus 
Newman induced platelet aggregation. As hypothesised, high dose anfibatide 
(32 µg/ml) had no significant effect on S. aureus induced aggregation in whole 
blood, n=3, analysed using a Multiplate analyser (p=0.104).  
 
S. sanguinis 133-79 induces platelet aggregation through the GPIb receptor. It 
was expected that the GPIb antagonist anfibatide would inhibit aggregation 
induced by this bacterial strain. Whole blood from six healthy donors was 
tested. In three of these donors, anfibatide at 3.2 µg/ml, 10 µg/ml, and 32 
µg/ml had no significant effect on platelet aggregation (p=0.156). In the 
remaining three donors, anfibatide partially inhibited whole blood aggregation 
in a dose dependent manner (figure 3.11.1). Anfibatide at a final concentration 
of 32 µg/ml significantly inhibited aggregation by 49 ± 17% (p<0.05). AN51, an 
anti-GPIb antibody, partially and significantly inhibited aggregation by 53 ± 
17% (p=0.04), indicating that S. sanguinis 133-79 does cause aggregation 
through the GPIb receptor, at least in part (figure 3.11.2). 
 
 62 
Figure 3.11.1. Anfibatide inhibits S. sanguinis 133-79 induced aggregation in whole 
blood samples from half of healthy volunteers by 50%. In 3 of 6 healthy volunteers, 32 
µg/ml anfibatide inhibited whole blood aggregation by 49 ± 17%, p<0.05, compared to control 
samples which were incubated with PBS. In these three donors, the anti-GPIb antibody AN51 
significantly inhibited platelet aggregation by 53 ± 17%, p<0.05, ANOVA, n=3, error bars 
represent SEM.  
 
Figure 3.11.2. S. sanguinis 133-79 is inhibited by AN51 and high dose anfibatide, S. 
aureus Newman induced platelet aggregation is not inhibited by anfibatide in whole 
blood. High dose anfibatide (32 µg/ml) and the anti-GPIb antibody AN51 (12.5 µg/ml) both 
inhibit S. sanguinis 133-79 induced platelet aggregation in whole blood to the same extent. S. 
aureus Newman induced platelet aggregation is not significantly inhibited, compared to 
control samples incubated with PBS instead of anfibatide, p=0.104, ANOVA, n=3, error bars 
represent SEM.
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3.12. The effect of anfibatide on bacterial induced aggregations in PRP 
 
The effect of anfibatide on bacterial induced platelet aggregation in PRP was 
measured using two strains of S. sanguinis: S. sanguinis NCTC 7863, and S. 
sanguinis 133-79, both of which act through the GPIb receptor to cause 
platelet aggregation. Anfibatide at a final concentration of 10 µg/ml had no 
significant effect on platelet aggregation in PRP induced by either strain 
(figure 3.12.1). 
 
 
Figure 3.12.1. High dose anfibatide did not effect S. sanguinis induced aggregations in 
PRP, as measure by LTA. High dose anfibatide (10 µg/ml) did not significantly effect 
aggregation induced by S. sanguinis 133-79 (p=0.144) or S. sanguinis NCTC 7863 (p=0.802), 
compared to control samples which were not incubated with anfibatide, as measured by light 
transmission aggregometry, paired t-test, n=3-4, error bars represent SEM. 
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The lag time for S. sanguinis NCTC 7863 was 8.4 ± 0.8 minutes, and was not 
significantly affected by anfibatide treatment (p=0.356). The lag time for S. 
sanguinis 133-79 was 3.2 ± 0.6 minutes, and was not significantly altered by 
anfibatide (p=0.547) (figure 3.12.2).  
 
 
Figure 3.12.2. Anfibatide did not significantly affect lag time in bacterial induced 
aggregation in PRP. High dose anfibatide (10 µg/ml) did not significantly affect the lag time 
of S. sanguinis NCTC 7863 (p=0.356), or S. sanguinis 133-79 (p=0.547), compared to control 
samples which were not incubated with anfibatide, as measured by light transmission 
aggregometry, paired t-tests, n=3-4, error bars represent SEM. 
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Chapter 4: Discussion 
 
Anfibatide is a novel anti-GPIb antagonist that is entering Phase Ib-IIa trials in 
early 2015. This trial will investigate the pharmacokinetics of the compound so 
that an effective dose can be chosen with which to treat patients. For the 
compound to be used effectively in patients with non-ST segment myocardial 
infarction, or possibly in the future in patients suffering from other thrombotic 
disorders, the extent of drug binding needs to be established. This is 
particularly important when targeting the GPIb receptor as not only do platelet 
numbers vary between patients, but receptor numbers per platelet also vary. 
 
In a clinical setting, it is necessary to monitor the levels of many 
pharmaceutical agents in patients. For example, in warfarin treatment, drug 
levels and activity in patients must be constantly monitored in order to control 
bleeding risk and optimise drug efficacy. Warfarin is a commonly used 
anticoagulant that can prevent thrombosis and thromboembolism (49). There 
are three main approaches to measuring drug levels in patients: measuring 
plasma levels of the drug, measuring functional analysis, or measuring 
receptor binding. Measuring the plasma levels of a drug is not always 
accurate, particularly in the case of drugs that have high affinity binding to 
their target receptor. For example, even when aspirin levels are low, 
antiplatelet effects are still seen as the drug is bound to COX-1 in platelets 
rather than freely circulating in the plasma (54). Anfibatide is expected to have 
high affinity binding to the GPIb receptor, making this an inappropriate tool. 
Functional analysis for anti-platelet agents generally involves measuring 
platelet aggregation. Most aggregometers require manipulation of blood, 
which is time consuming and can lead to platelet activation. Furthermore, 
most hospitals do not have access to platelet aggregometers, and the majority 
of health professionals are not trained in the technique. There is also wide 
variation in the results obtained from different platelet functional tests, making 
them unreliable and inconsistent (24). Receptor binding is the most 
appropriate way to measure anfibatide levels in patients in clinical trials. 
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A receptor binding assay was previously developed in this lab for GPIIb/IIIa 
(55), and it is on this principle that the current GPIb receptor occupacy assay 
is based. The assay that we have developed measures total GPIb receptor 
numbers per platelet for each patient, and measures binding of anfibatide to 
the platelet with the anti-anfibatide antibody 1B9. Therefore, the percentage of 
GPIb receptors occupied by anfibatide can be calculated using our assay. 
This is a no-wash assay, meaning that both the primary and secondary 
antibodies must be used at saturating concentrations. The secondary 
antibody, IgG-FITC, was part of the platelet calibrator kit (Biocytex, France) 
and was pre-optimised, meaning that only the primary antibody had to be 
optimised. The primary antibody, 1B9, was found to detect optimal binding of 
anfibatide at 3.8 µg/ml. It is recommended that the primary antibody is not 
used in excess of 10 µg/ml as part of the platelet calibrator kit, which means 
that this dose of 1B9 is appropriate. As 1B9 concentration increased beyond 
3.8 µg/ml, 1B9 detection of anfibatide decreased. This could be due to excess 
1B9 binding the FITC-labelled antibody in the plasma, preventing binding to 
anfibatide. 
 
In order to detect total GPIb receptor numbers, an anti-GPIb antibody was 
required for the assay. Five anti-GPIb monoclonal antibodies were tested. It 
was found that high dose VM16d (20 µg/ml) was not affected by anfibatide. 
Since the receptor numbers indicated in flow cytometry studies using VM16d 
are similar to those reported when measuring anfibatide binding using 7.35 
µg/ml 1B9, this antibody was chosen to measure total GPIb receptor number. 
This study showed that GPIb receptor occupancy by anfibatide, calculated 
using the anti-GPIb antibody VM16d, was directly related to functional activity 
as measured by inhibition of ristocetin-induced platelet aggregation in whole 
blood. In a clinical setting, blood samples could be tested using this assay to 
determine the occupancy of GPIb receptors by anfibatide. Since the 
percentage correlates with functional studies, dosage of anfibatide can be 
adjusted in order maximise receptor occupancy, while minimising the dose so 
as to prevent possible side effects. In order for this assay to be used in this 
way, this would need to be tested in a clinical trial. 
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VM16d was chosen as the receptor numbers detected by it most closely 
matched binding sites detected by 1B9. However, since low dose VM16d 
binding to GPIb is partially inhibited by anfibatide, it may not be the ideal 
candidate to measure receptor numbers. 1B9 at 3.8 µg/ml detected 
approximately 60,000 binding sites, compared to only approximately 30,000 
receptors detected by the anti-GPIb antibodies WM23, ALMA 19, and SZ2. 
Assuming that the evidence pointing to anfibatide being a GPIb antagonist is 
correct, there are some explanations for double the receptor numbers 
detected by 1B9 binding compared to normal GPIb receptor numbers. 
Anfibatide may be forming dimers, onto which two 1B9 molecules bind. It is 
unknown where 1B9 binds to anfibatide, and there may be two binding sites 
on 1B9 for the compound. There could potentially be an additional pool of 
GPIb receptors that is undetectable by the monoclonal antibodies. Since 
neither WM23 or ALMA 19 are affected by anfibatide, and they detect 
approximately half the number of binding sites that 1B9 detects with 
anfibatide, these could possibly be used to measure total receptor numbers, 
and the measured total could be doubled before calculating receptor 
occupancy by anfibatide. 
 
The assay is simple to use, and is very quick. From the initial blood draw, the 
entire assay could be completed and analysed in two hours by someone 
trained in the technique. Whole blood can be used, meaning that preparation 
time is short. The fact that the blood does not need to be manipulated limits 
the possiblity of platelet activation which could affect the results. The assay is 
easily taught, and easily learned, and completely accessible by any laboratory 
or hospital facility that has access to a flow cytometer. The optimum doses of 
each antibody has been determined in this study, so no calculations or 
optimisation has to be carried out in individual facilities. These factors make it 
feasible for the assay to be widely used in hospitals where patients would be 
undergoing anfibatide treatment. The assay would have to be validated in a 
cinical study prior to use in the clinic. 
 
In this study, 10 µg/ml of anfibatide resulted in maximal binding, which was 
matched with close to complete inhibition of ristocetin-induced whole blood 
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aggregation. The dose of anfibatide being used in the clinical studies in China 
would produce an estimated final concentration of only 2 ng/ml. In this study, 
the lowest concentration of anfibatide tested was 0.1 µg/ml, which had no 
recorded occupancy of GPIb receptors, and had no functional effect on 
aggregation. The concentration used in China is approximately 5,000 times 
more dilute than the concentration we found to have maximal effect in healthy 
donor blood, yet they are reporting an anti-thrombotic effect. This substantial 
difference in reported effective dosage raises a number of questions. The 
journey of anfibatide from China to Ireland may effect its potency. The protein 
is being transported in a lyophilised state, and is stored and prepared in the 
same manner as it is in China, making this an unlikely cause of the 
discrepancy. A second possible explanation for the discrepancy could be 
population differences. Chinese donors may have a higher affinity for 
anfibatide than Irish donors. A study comparing European and Chinese 
donors response to anfibatide should be carried out in one laboratory under 
the same conditions in an attempt to explain this difference. 
 
Identification of the Anfibatide Binding Site 
 
The effect of anfibatide on anti-GPIb antibodies gives an insight into the 
possible binding site of the drug. Anfibatide had no effect on WM 23, AN 51, 
and ALMA 19 binding. This indicates that anfibatide does not bind to the 
macroglycopeptide region, or the vWF binding site on GPIbα. Anfibatide 
partially inhibited both VM16d and SZ 2, which bind to the thrombin binding 
site and the sulfated tyrosine region respectively. Anfibatide did not inhibit 
aggregation induced in PRP by thrombin at low dose or high doses. This 
indicates that the drug does not bind directly to the thrombin binding site 
where VM16d does. Thus we hypothesise that anfibatide binds to GPIbα in 
the region between the thrombin binding site, and the sulfated tyrosine region 
contained in residues 276 - 282.  
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Estimation of GPIb Receptor Numbers 
 
Five different anti-GPIbα antibodies were used in this study. Surprisingly, the 
antibodies had varying numbers of binding sites. It was anticipated that all 
antibodies would give similar receptor numbers, as they all bind to the same 
receptor, and all antibodies were tested in the same donor on the same day 
(n=3). WM23, SZ 2, and ALMA 19 all had a similar number of binding sites 
(27,000 – 30,000 receptors). Previous studies with WM23 demonstrated that 
there were approximately 21,000 binding sites (6). However their study 
indicated that there was wide variability in recepetor numbers depending on 
the donor, indicating that the results of our study are reasonable and in line 
with previous data. In our study, AN51, which binds to the vWF binding site on 
GPIbα, has had only 15,000 binding sites, significantly less than the other 
anti-GPIb antibodies. Previous studies with AN 51 indicated 22,000 binding 
sites, though once again there was high inter-donor variability (6, 9). VM16d 
had the highest receptor numbers, with an average of 40,880 binding sites. 
However, there was no statistical significance when comparing WM23, SZ 2, 
ALMA 19, and VM16d receptor numbers. Conventionaly, it is believed that 
there are 25,000 – 30,000 GPIb receptors per platelet, half the number of 
GPIIb-IIIa receptors present. This is in agreement with data from WM23, SZ 2, 
and ALMA 19. The higher numbers indicated by VM16d may indicate that 
more than one antibody binds to each GPIb receptor, or there may be 
clustering of the antibody on GPIb. The fact that AN51 binds half the number 
of receptors compared to the other antibodies suggests that perhaps AN51 
can only bind one GPIbα molecule per GPIb-IX-V complex, or cleavage of 
glycocalicin may be occurring. 
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Anfibatide and Bacteria-Platelet Interactions 
 
If anfibatide is demonstrated to be a clinically effective and safe anti-
thrombotic, it could theoretically be used to inhibit bacteria that activate 
platelets through the GPIb receptor. S. sanguinis 133-79 has been shown to 
activate platelets by directly interacting with GPIb (57). Anfibatide inhibited S. 
sanguinis 133-79 induced whole blood aggregation in a dose dependent 
manner, to the same extent as the anti-GPIb antibody AN51. It did not inhibit 
S. aureus Newman induced aggregation, which is stimulated directly through 
GPIIb/IIIa receptor activation (56). These results indicate that anfibatide may 
be useful and effective in preventing or treating bacterial-induced sepsis, 
initiated by the interaction of certain bacterial strains with platelets. In our 
study however, aggregation was only inhibited in three of six healthy donors. 
This suggests that the treatment would not be effective in all patients, possibly 
due variations in GPIb structure between donors. Anfibatide also had no effect 
on aggregation induced in PRP by S. sanguinis 133-79. There is a possibility 
that there is some component of the whole blood that is not present in PRP 
that affects the anfibatide - platelet interaction. Whole blood aggregations are 
mosre physiologically relevant than aggregations in PRP. The PRP 
aggregations were only carried out in four healthy donors, so it is possible, 
based on the donor variation seen in the whole blood study, that the sample 
size was too small to analyse the true effect of anfibatide.  
 
Whole Blood Aggregation 
 
Ristocetin is a commonly used platelet agonist that induces platelet 
aggregation through the GPIb receptor, closely mimicking the in vivo 
interaction between vWF and the GPIb-IX-V complex. Anfibatide inhibited 
ristocetin - induced platelet aggregation in whole blood and PRP. This is 
further confirmation that anfibatide is a GPIb antagonist.  
 
Whole blood aggregation is a straightforward and easily learned technique. 
Use of Multiplate software could allow professionals in a clinical setting to 
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complete functional testing, along with the flow cytometry based receptor 
occupancy assay, to confirm that patients receiving anfibatide treatment are 
being effectively treated. Whole blood aggregations require no manipulation of 
blood, meaning that preparation time for the assay is short, and minimising 
platelet activation due to inappropriate handling. Furthermore, the assay only 
takes a few minutes to complete, and analysis is simple and fast. Inhibition of 
ristocetin-induced aggregation correlates with receptor occupancy by 
anfibatide, meaning that it is an excellent indicator of anfibtide efficacy, and 
suggesting that there are no free GPIb receptors. This indicated that whole 
blood aggregation could be used as a functional assay alongside the flow 
cytometry assay. 
 
Anfibatide Specificity  
 
The results of this in vitro study indicate that anfibatide is a potentially safe 
anti-thrombotic therapeutic. Anfibatide did not cause platelet activation, or loss 
of single platelets. It had no effect on GPIIb-IIIa in a monoclonal antibody 
binding study, which indicates that it would not cause bleeding at low shear 
stress, where GPIIb-IIIa is most active. Anfibatide studies in S. aureus 
Newman aggregation, as well as the GPIIb-IIIa monoclonal antibody studies, 
indicate that the inhibitory activity is specific to GPIb. It also had no effect on a 
range of agonists, including ADP, thrombin, and arachidonic acid, suggesting 
no off target effects. This implies that in vivo, anfibatide could effectively 
inhibit thrombus formation at high shear stress, for example in atherosclerotic 
arteries, while leaving the GPIIb-IIIa interaction unffected. Since the GPIIb-IIIa 
interaction is predominant at low shear stress in the periphery, excessive and 
unwanted bleeding would be prevented, making anfibatide an enticing 
alternative to GPIIb-IIIa antagonists. 
 
Future Work 
 
Anfibatide needs to be validated in upcoming clinical trials in China. This 
assay will be validated in approximately 100 non-ST segment myocardial 
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infarction patients on site in a military hospital in Beijing, beginning in March 
2015. Further investigation is also required to elucidate the exact binding site 
of anfibatide in order to fully understand its mechanism of action.
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Conclusion 
 
A flow cytometry based receptor occupancy assay has been developed. The 
technique involves measuring total GPIb receptor numbers with the 
monoclonal antibody VM16d, measuring anfibatide binding, and calculating 
total receptor occupancy, which is an indicator of functional activity. The 
assay is simple and quick, and can be used alongside the Multiplate analyser 
to measure functional activity through whole blood platelet aggregation. The 
assay is appropriate to use in forthcoming clinical trials on anfibatide in China, 
and in clinical practice in the future. The binding site of anfibatide is 
hypothesised to lie between the thrombin binding site and the sulfated 
tyrosine residues on GPIbα. Anfibatide inhibits ristocetin-induced aggregation 
in a dose-dependent manner, and partially inhibited S. sanguinis 133-79 
induced aggregation in 50% of healthy donors, indicating its potential use for 
bacterial-induced sepsis. 
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